Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension study of long-term bimekizumab in moderate to severe hidradenitis suppurativa
MOH_2021-12-29_010157Phase 3Not yet recruiting
- Sponsor
- UCB
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of bimekizumab in hidradenitis suppurativa (HS) (2 arms), sponsored by UCB. Primary endpoint: Long-term safety of bimekizumab. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
bimekizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on MOH_2021-12-29_010157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-29_010157.